Latest filing published 17 Sept 2021 for Alimera Sciences INC.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Brian K. Halak: trading record in brief
Brian K. Halak (board member) discloses dealings in 16 companies, chiefly Orexigen Therapeutics, Inc., Dicerna Pharmaceuticals Inc and Clovis Oncology, Inc. Over a trading history stretching from 12 September 2007 to 17 September 2021, the count stands at 126 filings.
On the open market, the record shows 53 purchases worth €69.3M and 25 sales worth €17.5M. Purchases outweigh sales by €51.8M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 share grants and 2 option exercises.
The median purchase comes to €145k.
On 17 September 2021 came the latest disclosure, a transaction in Alimera Sciences Inc. The clock since the last published purchase (25 July 2013) now reads 4,854 days. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Brian K. Halak
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 215 shares0Common StockSEC:0000904454-21-000668:0
- 189,359 shares@ US$13.4717.0% of flowCommon StockSEC:0000904454-18-000702:0
- 1,412 shares@ US$13.470.1% of flowCommon StockSEC:0000904454-18-000702:1
- 39,606 shares@ US$12.983.4% of flowCommon StockSEC:0000904454-18-000702:2
- 295 shares@ US$12.980.0% of flowCommon StockSEC:0000904454-18-000702:3
- 102,067 shares@ US$13.188.9% of flowCommon StockSEC:0000904454-18-000702:4
- 761 shares@ US$13.180.1% of flowCommon StockSEC:0000904454-18-000702:5
- 1,489 shares@ US$14.160.1% of flowCommon StockSEC:0000904454-18-000702:6
- 11 shares@ US$14.160.0% of flowCommon StockSEC:0000904454-18-000702:7
- 188,867 shares@ US$13.3716.9% of flowCommon StockSEC:0000904454-18-000697:6
- 152,364 shares@ US$13.6813.9% of flowCommon StockSEC:0000904454-18-000691:0
- 1,136 shares@ US$13.680.1% of flowCommon StockSEC:0000904454-18-000691:1
- 90,918 shares@ US$14.318.7% of flowCommon StockSEC:0000904454-18-000691:2
- 678 shares@ US$14.310.1% of flowCommon StockSEC:0000904454-18-000691:3
- 128,670 shares@ US$13.6011.7% of flowCommon StockSEC:0000904454-18-000691:4
- 959 shares@ US$13.600.1% of flowCommon StockSEC:0000904454-18-000691:5
- 188,167 shares@ US$13.3716.9% of flowCommon StockSEC:0000904454-18-000691:6
- 1,408 shares@ US$13.370.1% of flowCommon StockSEC:0000904454-18-000691:7
- 21,041 shares@ US$7.000.9% of flowCommon StockSEC:0000904454-18-000422:0
- 156 shares@ US$7.000.0% of flowCommon StockSEC:0000904454-18-000422:1
- 10,195 shares@ US$14.450.9% of flowCommon StockSEC:0000904454-18-000422:2
- 76 shares@ US$14.450.0% of flowCommon StockSEC:0000904454-18-000422:3
- 1,692 shares0Common StockSEC:0000904454-15-000486:0
- 33,890 sharesCommon StockSEC:0000904454-14-000293:1
- 1,987,049 sharesCommon StockSEC:0000904454-14-000293:0
25 of 77 declarations
